The Middle East and Africa Genetic Testing Market is expected to grow with a CAGR of 13.6% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/middle-east-and-africa-genetic-testing-market
The Middle East and Africa genetic testing market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.
The major players dealing in the market are engaged in developing and producing products utilized in the treatment, among others.
For instance,
- In September, 2022 Illumina Inc., which is one of the major players in the market, has 20 NGS instruments in its product portfolio. The revenue of the sequencing segment increased in the fiscal year 2020 due to the sale of these instruments and consumables needed for next-generation sequencing and COVID-19 research
Bayer AG is the dominating leader in the Middle East and Africa genetic testing market. The other players in this market are Abbott, 23ANDME, Inc., Danaher, Myriad Genetics, Inc., OCP Medical Centre, L.L.C, Healthchecks360, Bayer AG, BioReference Health, LLC (a subsidiary of OPKO Health, Inc.), FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C.), Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Biocartis, Eurofins Scientific, PerkinElmer Inc., ELITechGroup, F. Hoffmann-La Roche Ltd., Illumina, Inc., QIAGEN, BIO-HELIX, and PacBio among others.
Bayer AG
Bayer AG is headquartered in Leverkusen, Germany, and was founded in 1863. The company focuses on creating value for its customers, stockholders, and employees while strengthening the company's earning power. The company operates various business segments such as crop science, pharmaceuticals, and consumer health, where pharmaceuticals is the market-focused segment. The company offers products such as prescription products, specialty therapeutics, and radiology, where specialty therapeutics is the market-focused category.
The company has a wide global presence across Africa, Asia, Australia, New Zealand, Europe, Latin America, The Middle East, and North America.
Abbott
Abbott was founded in 1888 and headquartered in Florida, U.S. The company focuses on manufacturing diagnostics, medical devices, nutrition and branded generic pharmaceuticals that help consumers and its family lead a healthier life with all unlimited possibilities. The company offers business segments such as pharmaceutical products, nutritional products, diagnostic products, and medical devices, where diagnostic products is the market-focused business segment. The company offers product categories such as consumers and healthcare professionals, where healthcare professionals is the market-focused category.
The company has subsidiaries such as Abbott Ireland (Ireland), Abbott Laboratories Argentina, S.A. (Argentina), Abbott Japan Co., Ltd. (Japan), Abbott Scandinavia AB (Sweden), Abbott Canada (Canada) among others.
Illumina, Inc.
Illumina was founded in 1998 and is headquartered in California, U.S. The company is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. The business operates business segments such as consumables, instruments, services, and other revenue. The company offers product categories such as sequencing kits, microarray kits, clinical research products, in vitro diagnostic (IVD) products, informatics products, molecular biology reagents, accessory products, and service & training products, all of which are also market-focused categories.
The company has subsidiaries, including Illumina Australia Pty. Ltd. (Australia), Illumina Cambridge, Ltd. (Canada), Illumina Canada, Inc. (Canada), Illumina GmbH (Germany), Illumina US Manufacturing Operations, Inc. (U.S.) among others.
For instance,
-
- In September, 2022 Illumina Inc., which is one of the major players in the market, has 20 NGS instruments in its product portfolio. The revenue of the sequencing segment increased in the fiscal year 2020 due to the sale of these instruments and consumables needed for next-generation sequencing and COVID-19 research Sequencing revenue growth increased by approximately 25% compared to the prior year period demonstrating the solid recovery from the COVID-19 pandemic
Sequencing instrument growth of approximately 120% compared to the prior year period, reflecting strong performance across all instrument categories
The company has a wide presence in Asia-Pacific, Europe, the Americas, and the Middle East and Africa.
